Navigation Links
QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
Date:3/31/2009

locally in the vagina. No SERMs that are currently approved and marketed in the United States have been shown to have beneficial effects on vaginal tissue and none are approved for use in treating vaginal symptoms.

About QuatRx

QuatRx Pharmaceuticals is focused on the discovery, licensing, development and commercialization of compounds in the endocrine, metabolic and cardiovascular therapeutic areas. In addition to Ophena(TM), QuatRx has three other product candidates in clinical development and an advanced preclinical program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 as an oral treatment for the symptoms of secondary hypogonadism and other conditions in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel Vitamin D analogue, is in Phase 2 clinical trials for the treatment of psoriasis through QuatRx's partner, Galderma. QuatRx's preclinical program is designed to address sex steroid dependent diseases through inhibition of 17beta-HSD enzymes. In Europe, QuatRx operates through its Finnish subsidiary, Hormos Medical Ltd, located in Turku, Finland. For press releases and other Company information, please visit www.quatrx.com.


'/>"/>
SOURCE QuatRx Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
4. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
5. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
6. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... BOSTON , July 6, 2015 ... Inc. (NASDAQ: ISIS ), announced today that ... Orphan Drug Designation to volanesorsen (ISIS-APOCIII Rx ) ... Syndrome (FCS).  FCS is a rare genetic disease ... of pancreatitis. In a Phase 2 study published ...
(Date:7/5/2015)... 2015 Nihon University is pleased to ... Medical-Engineering Collaboration "Medicine Definitely Jumps Up with 8K" ... Tokyo, Japan . Many experts ... will present their achievements and future prospects on ... produced with 8K technology. (Documentation: ...
(Date:7/3/2015)... Un fournisseur mondial de ... l,hypertension, le diabète et les troubles thyroïdiens en ... plateformes éducatives gratuites et d,une conférence majeure dédiée ... http://photos.prnewswire.com/prnh/20150630/227090 ) , Les formations ... , Prendre en charge l,hypertension en ligne ...
Breaking Medicine Technology:Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Asie centrale et du Sud-Est grâce à la formation médicale 3
... EF Johnson Technologies, Inc. (Nasdaq: EFJI ), a ... results for the quarter ended September 30, 2009. Revenues ... was $1.6 million, or $(0.06) per diluted share, for the ... pleased with our orders and contract awards, the third quarter ...
... Inc. (NYSE: ZMH ; SIX: ZMH) announced today that ... unsecured notes in an underwritten public offering consisting of $500.0 ... 5.75% notes due 2039. The 10-year notes were priced to ... 30-year notes were priced at 135 basis points above their ...
Cached Medicine Technology:EF Johnson Technologies Announces Third Quarter Results 2EF Johnson Technologies Announces Third Quarter Results 3EF Johnson Technologies Announces Third Quarter Results 4EF Johnson Technologies Announces Third Quarter Results 5EF Johnson Technologies Announces Third Quarter Results 6EF Johnson Technologies Announces Third Quarter Results 7EF Johnson Technologies Announces Third Quarter Results 8Zimmer Holdings, Inc. Agrees to Sell $1 Billion of Senior Notes 2
(Date:7/6/2015)... ... July 06, 2015 , ... Shortly after opening her second practice in Signal ... doctors working on a lien basis. Dr. Lim had previously worked with Dr. ... two Cambodian refugees, Dr. Lim suffered with back pain herself throughout high school. ...
(Date:7/6/2015)... UK (PRWEB) , ... July 06, 2015 , ... The ... billion in 2014. It is expected to grow at a CAGR of over 3.2 ... 2021. , The growth is likely to be mainly spurred by an anticipated launch ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... southern California, has partnered with Woodbridge Walk-In Urgent Care to offer on-site health ... other serious medical conditions. Screenings are affordable and accurate and run about an ...
(Date:7/6/2015)... ... July 06, 2015 , ... With a ... once again teamed up with Family Emergency Shelter Coalition (FESCO) and announced a ... FESCO was created especially to provide emergency services and support for homeless families, ...
(Date:7/6/2015)... ... July 06, 2015 , ... The School of ... to support a three-year effort to reduce rates of diabetes and cardiovascular disease ... partnership with the Morehouse School of Medicine’s Prevention Research Center and the Satcher ...
Breaking Medicine News(10 mins):Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2
... 15, CDC says , , WEDNESDAY, May 6 (HealthDay News) -- ... mild, those who are hospitalized due to more severe disease ... In fact, the median age of hospitalized individuals with swine ... seasonal flu, U.S. Centers for Disease Control and Prevention acting ...
... practices to prevent the spread of flu- proper hand washing, visiting ... , WASHINGTON, May 6 /PRNewsiwre-USNewswire/ -- ... outbreak, but more than half of the people are paying extra ... themselves from the virus, according to a new poll by the ...
... LAS VEGAS, May 6 Results of the Clopidogrel Medco ... the anti-clotting benefits of clopidogrel (Plavix) may be reduced when ... inhibitors (PPIs). In the study, patients taking clopidogrel and ... 50% increase in the ...
... 6 Litigation surrounding health and damage claims relating ... conference to be held in New Orleans. The ... Baron & Budd, according to HB Litigation Conferences LLC, ... the subject, one for insurance attorneys and in-house counsel, ...
... and memory loss motivates the birth of a new ... 6 In Chicagoland alone, more than ... memory loss conditions while 320,894 are at high risk ... households don,t have at least one caregiver with the ...
... tied to surgery, anesthesia, experts note, , , WEDNESDAY, May ... people with Alzheimer,s who are hospitalized might accelerate their ... that people with Alzheimer,s who had an episode of ... cognitive decline that was three times faster than that ...
Cached Medicine News:Health News:Younger Age of Severe Swine Flu Cases Worries Experts 2Health News:Younger Age of Severe Swine Flu Cases Worries Experts 3Health News:Younger Age of Severe Swine Flu Cases Worries Experts 4Health News:Younger Age of Severe Swine Flu Cases Worries Experts 5Health News:Younger Age of Severe Swine Flu Cases Worries Experts 6Health News:Younger Age of Severe Swine Flu Cases Worries Experts 7Health News:Younger Age of Severe Swine Flu Cases Worries Experts 8Health News:Younger Age of Severe Swine Flu Cases Worries Experts 9Health News:Younger Age of Severe Swine Flu Cases Worries Experts 10Health News:Younger Age of Severe Swine Flu Cases Worries Experts 11Health News:Younger Age of Severe Swine Flu Cases Worries Experts 12Health News:Younger Age of Severe Swine Flu Cases Worries Experts 13Health News:Younger Age of Severe Swine Flu Cases Worries Experts 14Health News:Polls Show Americans Concerned About Swine Flu, Taking Actions to Protect Themselves 2Health News:Polls Show Americans Concerned About Swine Flu, Taking Actions to Protect Themselves 3Health News:SCAI Statement on 'A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study' 2Health News:HB Litigation Conferences Announces Conference and Two Teleconferences on Chinese Drywall Litigation and Insurance 2Health News:Latinos in Chicago and Suburbs Face Alarming Numbers of Cases of Alzheimer's Disease While Thousands More are at Risk of Being Diagnosed 2Health News:Latinos in Chicago and Suburbs Face Alarming Numbers of Cases of Alzheimer's Disease While Thousands More are at Risk of Being Diagnosed 3Health News:Delirium Episodes Could Hasten Alzheimer's-Linked Decline 2Health News:Delirium Episodes Could Hasten Alzheimer's-Linked Decline 3
ELISA Microplate Washer, Manual...
Designed to meet the demands of today's laboratories for RO water....
... 8000 L/day of Type III Laboratory-grade Water, ... produce up to 8000 L/day of Type ... One Complete Purification and Control Unit, RiOs ... system, providing total control of all parameters ...
... Produce Up to 8000 L/day of Type ... are designed to produce up to 8000 ... potable tap feedwater., One Complete Purification and ... into a centralized system, providing total control ...
Medicine Products: